December 4-5, 2019

Boston, MA

Day One
Tuesday 11th December, 2018

Day Two
Wednesday 12th December, 2018

08.20
Chair’s Opening Remarks

  • Vincenzo di Marzo Canada Excellence Research Chair, Université Laval & Research Director , CNR

08.30
Welcome Panel: Bringing Together Industry and Academia

  • Vincenzo di Marzo Canada Excellence Research Chair, Université Laval & Research Director , CNR
  • Tamás Biro Director General, Hungarian Center of Excellence for Molecular Medicine & Professor, Department of Immunology, University of Debrecen
  • Andrea Small- Howard Chief Scientific Officer , GB Sciences

Synopsis

  • What Are the Common Challenges and Goals?
  • How Can Each Side Be Supported?

Exploring the Complex Multi-Target Pharmacology of Cannabinoids

09.00
The Complex Polypharmacology of Phytocannabinoids and How to Deal With it for the Development of New Medicines

  • Vincenzo di Marzo Canada Excellence Research Chair, Université Laval & Research Director , CNR

Synopsis

  • Non-psychotropic plant cannabinoids, exemplified by cannabidiol, show promising multiple therapeutic properties, most likely due to their capability of modulating the activity of several molecular targets, not all of which belong to the endocannabinoid system
  • Fully understanding the implications of the polypharmacology of these phytocannabinoids is a complex task, and predicting their efficacy in a given disorder will require new bioinformatics and systems biology approaches
  • Nevertheless, clinical data exist on the use of cannabidiol and other multi-target nonpsychotropic cannabinoids in pathologies ranging from schizophrenia and metabolic disorders to epilepsy and cancer

09.30
Developments in our Understanding of the Endocannabinoid System

  • Tamás Biro Director General, Hungarian Center of Excellence for Molecular Medicine & Professor, Department of Immunology, University of Debrecen

Synopsis

  • Get an overview of the most recent updates on our understanding of the Endocannabinoid System
  • Take a detailed look at the ways we can select a target effectively to elicit the desired clinical effect

10.00
Morning Refreshments and Speed Networking

11.30
Cannabinoid Receptor Intercepting Proteins (CRIPs): An Introduction

Synopsis

  • The CB1 cannabinoid receptor is a G protein coupled receptor for agonists such as phytocannabinoid delta-9-THC, endocannabinoids anandamide and 2-arachidonylglycerol, and synthetic compounds such as CP55940 and WIN55212-2.
  • Agonist-stimulation of the CB1 receptor is primarily mediated by members of the Gi family (Gi1, Gi2, Gi3, Go) of G proteins.
  • However, proteins including beta-arrestins 1 and 2, and Cannabinoid Receptor Interacting Protein 1a (CRIP1a) also modify CB1 receptor responses in neurons and other cells.
  • Drug design to selectively promote therapeutic versus untoward responses can be influenced by our understanding of associated protein interactions

12.00
Putting the Patient First: Fast Acting Delivery Methods for CBD Products

12.10
Mastermind Discussion: Identifying the Key Challenges at the Various Stages of Development for a Cannabinoid-Containing Therapy

Synopsis

• In groups you will be part of an open discussion on how different parts of the development process could be impacted by using one or multiple Cannabinoids in a therapeutic. The outcomes of these discussions will then be collected and redistributed after the conference. The topics you will discuss, include:
• Formulation
• Drug Delivery System Design
• Preclinical Testing
• Clinical Trials

12.40
Lunch and Networking

Preclinical Formulation, Drug Delivery System Design & Testing

14.00
Unique Methods to Identify Strong Lead Compounds

Synopsis

  • Understand GB Sciences’ lead identification strategy
  • Explore different methodologies and their effectiveness in the Cannabinoid research field

14.30
Efficacy of THX-110, a Proprietary Therapeutic Combination of (D9- tetrahydracannabinol and Palmitoylethanolamide) for Adults with Tourette Syndrome

Synopsis

  • There are few effective pharmacological treatments for Tourette syndrome (TS). Many patients with TS experience impairing tic symptoms despite use of available evidence-based treatments
  • Several lines of evidence suggest that cannabis (Cannabis sativa) and 9- tetrahydracannabinol (9-THC) may be effective in the treatment of tic disorders
  • By using THX-110, we hoped to use the entourage effect to deliver the therapeutic benefits of 9-THC in reducing tics with decreased psychoactive effects using Palmitoylethanolamide (PEA)
  • Tic symptoms significantly improved over time with THX-110 treatment. Improvement in tic symptoms was statistically significant within 1 week of starting treatment. THX-110 treatment led to an average improvement in tic symptoms of over 20% or a 7-point decrease in YGTSS score

15.00
Afternoon Refreshments & Poster Session

16.00
Keynote Talk: The Approval of Epidiolex in the US

  • Ben Whalley Director of Research, GW Pharmaceuticals Ltd

Synopsis

  • Narrative of the journey to FDA approval of Epidiolex for Dravet syndrome and Lennox Gastaut syndrome
  • Lessons learned from approval of the first cannabis-derived prescription medicine in the US

16.30
Pills, Sprays, Ointments, Soluble Strips, What Else? A Deep Look at Novel Delivery Systems

  • Zohar Koren Chief Executive Officer and Founder , SciCann

Synopsis

  • What delivery systems and administration routes are available for pharmaceutical cannabinoids?
  • Advantages and disadvantages of oral, buccal and pulmonary delivery routes.
  • Liposomes, nano-ghosts and targeted therapies – what will the future look like for cannabinoid delivery systems?

16.45
End of Day 1

16.45
Poster Session

Synopsis

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity toget face-to-face time with many of the brightest minds working in Cannabinoid drug development to establish meaningful business relationships.

17.45
Chair’s Closing Remarks

  • Vincenzo di Marzo Canada Excellence Research Chair, Université Laval & Research Director , CNR